Conditions: Basal Cell Carcinoma
Keywords: BCC Hedgehog Pathway Inhibitor Hedgehog Basal Cell Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 104
Healthy volunteers: no

Brief summary:
This was a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients received vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.

Detailed description:

Arms:
arm 1: Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.

Interventions: intervention 1: Vismodegib 150 mg
Intervention descriptions: intervention 1: Vismodegib 150 mg was provided in hard gelatin capsules.

Protocol document: